Modern confirms the efficacy and calls for the emergency use of the vaccine

North American pharmaceutical Modernist applied for permission on Monday for the use of its covid-19 vaccine, after confirming the efficacy is 94.1%.

In this regard, the company has asked the American authorities (FDA) to use the vaccine in an emergency, as well as conditional approval by the European Medicines Agency.

Preliminary results were published two weeks ago that put the vaccine’s effectiveness at 94.5%, but the American company now announces that no safety concerns have been reported, which is why it has a 100% success rate. in the prevention of severe cases, with more severe symptoms.

“This positive primary analysis confirms our vaccine’s ability to prevent covid-19 disease with an efficacy of 94.1% and, more importantly, the ability to prevent severe cases of covid-19. We believe our vaccine it will provide a powerful new tool that will change the course of this pandemic and help prevent severe cases, hospitalizations and deaths, “explained Stéphane Bancel, Moderna’s executive director.

According to the statement released by Moderna, the phase 3 primary efficacy analysis of the COVE study for the Covid-19 vaccine was performed on 196 patients with confirmed covid-19 cases, of which 30 were serious. In this sense, the vaccine was found to be effective in 94.1% of cases, while severe cases were 100% effective in severe cases.

Moderna’s note adds that the vaccine’s efficacy “was consistent with respect to age, race, ethnicity and sex,” with no cases with serious effects recorded so far.